University of Minnesota Department of Gynecologic Oncology
Ovarian Cancer Clinical Research Trials

**FATE-NK100: Intraperitoneal (IP) Delivery of Adaptive Natural Killer (NK) Cells with IP IL-2**

- **Targeted Disease:** Platinum sensitive and platinum resistant recurrent ovarian cancer
- **Treatment Line:** 2nd line or greater
- Immunotherapy trial using injections of FATE-NK100 to support and strengthen the immune system. The goal is to delay the time it takes for cancer to recur.
- **Principal Investigator:** Dr. Melissa Geller

***** THIS STUDY IS CURRENTLY BEING FUNDED BY A MOCA GRANT *****

**ALT-803: Intraperitoneal ALT-803 Followed by Subcutaneous ALT-803 for Maintenance Therapy**

- **Targeted Disease:** Stage III and IV ovarian cancer
- **Treatment Line:** Maintenance after frontline therapy – within 3 months of last chemo infusion
- Immunotherapy trial using injections of ALT-803 to support and strengthen the immune system. The goal is to delay the time it takes for cancer to recur.
- **Principal Investigator:** Dr. Melissa Geller

***** THIS STUDY IS CURRENTLY BEING FUNDED BY A MOCA GRANT *****

**Tesaro FIRST: [Standard of Care (SOC)] vs [SOC + Niraparib] vs [SOC + TSR-042 + Niraparib]**

- **Targeted Disease:** Stage III or IV epithelial ovarian cancer
- **Treatment line:** Frontline & maintenance
- Adds an immunotherapy PDL-1 inhibitor (TSR-042) during frontline chemotherapy. A PARP inhibitor (Niraparib) and TSR-042 are then given for maintenance therapy for up to 3 years.
- **Principal Investigator:** Dr. Deanna Teoh

**NRG GY-005: [Standard of Care] vs [Cediranib + Olaparib] vs [Olaparib]**

- **Targeted Disease:** Platinum resistant recurrent cancer (recurred within 6 months of last chemo)
- **Treatment Line:** 2nd line or greater
- Tests the efficacy of a VEGF inhibitor (Cediranib) combined with a PARP inhibitor (Olaparib). Other arms include the standard of care treatment and single agent Olaparib.
- **Principal Investigator:** Dr. Melissa Geller

**FATE-NK100: Intraperitoneal (IP) Delivery of Adaptive Natural Killer (NK) Cells with IP IL-2**

- **Targeted Disease:** Platinum sensitive and platinum resistant recurrent ovarian cancer
- **Treatment Line:** 2nd line or greater
- Immunotherapy trial that isolates and strengthens Natural Killer (NK) Cells from a relative donor. FATE-NK100 is then administered through a peritoneal port. The NK cells are kept alive by then administering IL-2
- **Principal Investigator:** Dr. Melissa Geller

**Upcoming** NanoString: Pembrolizumab in Recurrent Immunoreactive Ovarian Cancer

- **Targeted Disease:** Recurrent ovarian cancer, both platinum sensitive and platinum resistant
- **Treatment Line:** 2nd line or greater
- Patient’s tumor is tested using NanoString gene profiling. This determines if the cancer is immunoreactive. Immunoreactive subtypes are then treated with pembrolizumab (Keytruda) immunotherapy
- **Principal Investigator:** Dr. Boris Winterhoff

**Upcoming** Novocure INNOVATE: Taxol + Novocure Tumor Treating Fields Belt

- **Targeted Disease:** Platinum resistant recurrent cancer (recurred within 6 months of last chemo)
- **Treatment Line:** 2nd line or greater
- Patients wear a Novocure belt with Tumor Treating Fields (TTF) 18+ hours per day, in addition to receiving Taxol every 3 weeks. TTF uses electric fields to disrupt cancer cell division, inhibit tumor growth, and leads to cell death
- Visit Novocure.com and Novocure.com/mechanism-of-action for more information
- **Principal Investigator:** Dr. Deanna Teoh

Interested in participating in a clinical trial?

Call 855-486-7226 to schedule appointment